<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203537</url>
  </required_header>
  <id_info>
    <org_study_id>CA-PS-208</org_study_id>
    <nct_id>NCT04203537</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008</brief_title>
  <official_title>A Two-Part, Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Adaptive Safety, Pharmacokinetics and Preliminary Efficacy Study of CA-008 in Patients Undergoing Total Knee Arthroplasy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concentric Analgesics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concentric Analgesics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the pilot Part A of this study, multiple doses of CA-008 will be evaluated for safety,
      tolerability and PK. Doses will then be selected for the expanded, main part of the study
      where CA-008 will be compared to placebo. Patients will have serial assessments of safety,
      PK, and drug effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not provided
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A: dose ascending, placebo-controlled Part B: randomized, double-blind, placebo-controlled, parallel design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity Scores</measure>
    <time_frame>Up through 96 hours</time_frame>
    <description>None in Part A; In Part B, pain intensity scores (using a Numeric Rating Scale of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable) at T96 hours for CA-008 vs placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>Up through Day 29</time_frame>
    <description>None in Part A; In Part B, for each CA-008 versus placebo comparison, total opioid consumption in oral morphine equivalents</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Post-surgical Pain</condition>
  <arm_group>
    <arm_group_label>CA-008</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA-008</intervention_name>
    <description>Single administration of CA-008 versus placebo</description>
    <arm_group_label>CA-008</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled elective Total Knee Arthroplasty (TKA) under spinal anesthesia

          -  Aged 18-80 years old

          -  ASA physical class 1, 2, or 3

          -  BMI &lt;/= 42 kg/m2

          -  Generally healthy

        Exclusion Criteria:

          -  Concurrent condition requiring analgesic treatment during study period

          -  Opioid tolerant

          -  Known allergy to capsaicin or other study medication

          -  Use of prohibited medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daneshvari Solanki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HD Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Huels, MS</last_name>
    <phone>4154847921</phone>
    <email>vhuels@concentricanalgesics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sam Teichman, MD</last_name>
    <phone>4154847921</phone>
    <email>steichman@concentricanalgesics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lotus Clinical Reserach, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siri Chew, M.P.H.</last_name>
      <phone>626-397-2390</phone>
      <email>schew@lotuscr.com</email>
    </contact>
    <investigator>
      <last_name>Alina Beaton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Surgical Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shruti Kolte</last_name>
      <phone>346-401-7712</phone>
      <email>shruti@researchhd.com</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Howard</last_name>
      <phone>281-770-5752</phone>
      <email>lauren@researchhd.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daneshvari Solanki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plano Surgical Hospital</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Ibarra</last_name>
      <email>libarra@lotuscr.com</email>
    </contact>
    <investigator>
      <last_name>Julie Greene, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

